<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: allograft bone tissue", fill: "#6c541e"},
{source: "2: allograft bone tissue", target: "5: allograft bone tissue which", fill: "#fadfad"},
{source: "5: allograft bone tissue which", target: "5: financial condition", fill: "#fadfad"},
{source: "5: financial condition", target: "5: operations", fill: "#fadfad"},
{source: "5: allograft bone tissue which", target: "7: allograft bone tissue processing", fill: "#6ca0dc"},
{source: "7: allograft bone tissue processing", target: "7: primarily depends upon", fill: "#6ca0dc"},
{source: "7: primarily depends upon", target: "7: availability", fill: "#6ca0dc"},
{source: "7: availability", target: "7: connective tissue from human donors", fill: "#6ca0dc"},
{source: "7: connective tissue from human donors", target: "7: cadaveric", fill: "#6ca0dc"},
{source: "7: cadaveric", target: "7: internationally", fill: "#6ca0dc"},
{source: "7: allograft bone tissue processing", target: "8: current clients", fill: "#7b1113"},
{source: "8: current clients", target: "8: increased willingness", fill: "#7b1113"},
{source: "8: increased willingness", target: "8: bone tissue", fill: "#7b1113"},
{source: "8: current clients", target: "13: investments", fill: "#035096"},
{source: "13: investments", target: "13: distribution efforts", fill: "#035096"},
{source: "13: distribution efforts", target: "13: future programs", fill: "#035096"},
{source: "13: future programs", target: "13: initiatives which may", fill: "#035096"},
{source: "13: initiatives which may", target: "13: available cash balances", fill: "#035096"},
{source: "13: investments", target: "21: adversely impacted by", fill: "#5d3954"},
{source: "21: adversely impacted by", target: "21: focus on direct", fill: "#5d3954"},
{source: "21: focus on direct", target: "21: distribution", fill: "#5d3954"},
{source: "21: adversely impacted by", target: "28: bone tissue", fill: "#000080"},
{source: "28: bone tissue", target: "28: process competes", fill: "#000080"},
{source: "28: process competes", target: "28: bone graft", fill: "#000080"},
{source: "28: bone graft", target: "28: growth factors", fill: "#000080"},
{source: "28: growth factors", target: "28: allograft bone tissue processed by others", fill: "#000080"},
{source: "28: bone tissue", target: "29: Autograft ", fill: "#d10056"},
{source: "29: Autograft ", target: "29: traditionally been", fill: "#d10056"},
{source: "29: traditionally been", target: "29: primary choice", fill: "#d10056"},
{source: "29: primary choice", target: "29: autograft bone tissue", fill: "#d10056"},
{source: "29: autograft bone tissue", target: "29: still used extensively", fill: "#d10056"},
{source: "29: still used extensively", target: "29: United States", fill: "#d10056"},
{source: "29: Autograft ", target: "36: compete with such entities on", fill: "#f49ac2"},
{source: "36: compete with such entities on", target: "36: advanced processing technology", fill: "#f49ac2"},
{source: "36: advanced processing technology", target: "36: bone tissue", fill: "#f49ac2"},
{source: "36: bone tissue", target: "36: processing yields", fill: "#f49ac2"},
{source: "36: compete with such entities on", target: "START_HERE", fill: "#f49ac2"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Oil and Gas Storage and Transportation</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Transportation</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bone_grafting">Bone grafting</a></td>
      <td>Bone grafting is a surgical procedure that replaces missing bone in order to repair bone fractures that are extremely complex, pose a significant health risk to the patient, or fail to heal properly. Some small or acute fractures can be cured without bone grafting, but the risk is greater for large fractures like compound fractures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Allotransplantation">Allotransplantation</a></td>
      <td>Allotransplant (allo- meaning "other" in Greek) is the transplantation of cells, tissues, or organs to a recipient from a genetically non-identical donor of the same species. The transplant is called an allograft, allogeneic transplant, or homograft.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Graft_(surgery)">Graft (surgery)</a></td>
      <td>Grafting refers to a surgical procedure to move tissue from one site to another on the body, or from another creature, without bringing its own blood supply with it.  Instead, a new blood supply grows in after it is placed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bone_tumor">Bone tumor</a></td>
      <td>A bone tumor is an abnormal growth of tissue in bone, traditionally classified as noncancerous (benign) or cancerous (malignant). Cancerous bone tumors usually originate from a cancer in another part of the body such as from lung, breast, thyroid, kidney and prostate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Organ_transplantation">Organ transplantation</a></td>
      <td>Organ transplantation is a medical procedure in which an organ is removed from one body and placed in the body of a recipient, to replace a damaged or missing organ.  The donor and recipient may be at the same location, or organs may be transported from a donor site to another location.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Artificial_bone">Artificial bone</a></td>
      <td>Artificial bone refers to bone-like material created in a laboratory that can be used in bone grafts, to replace human bone that was lost due to severe fractures, disease, etc.Bone fracture, which is a complete or partial break in the bone, is a very common condition that has more than three million US cases per year. Human bones have the ability to regenerate themselves by cycle of bone resorption and bone formation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biomedical_Tissue_Services">Biomedical Tissue Services</a></td>
      <td>Biomedical Tissue Services (BTS) was a Fort Lee, New Jersey, human tissue recovery firm that was shut down by the U.S. Food and Drug Administration (FDA) on October 8, 2005, after its president, Dr. Michael Mastromarino, and two other employees were convicted of illegally harvesting human bones, organs, tissue and other cadaver parts from individuals awaiting cremation, for forging numerous consent forms, and for selling the illegally obtained body parts to medical companies without consent of their families.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Transplantable_organs_and_tissues">Transplantable organs and tissues</a></td>
      <td>Transplantable organs and tissues may both refer to organs and tissues that are relatively often or routinely transplanted (here "main organs and tissues"), as well as relatively seldom transplanted organs and tissues and ones on the experimental stage.\n\n\n== Main organs ==\n\n\n=== Heart ===\n\nHeart transplantation is performed on patients with end-stage heart failure or severe coronary artery disease.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation">Hematopoietic stem cell transplantation</a></td>
      <td>Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin).It is most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bone_resorption">Bone resorption</a></td>
      <td>Bone resorption is resorption of bone tissue, that is, the process by which osteoclasts break down the tissue in bones and release the minerals, resulting in a transfer of calcium from bone tissue to the blood.The osteoclasts are multi-nucleated cells that contain numerous mitochondria and lysosomes.  These are the cells responsible for the resorption of bone.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bone_remodeling">Bone remodeling</a></td>
      <td>Bone remodeling (or bone metabolism) is a lifelong process where mature bone tissue is removed from the skeleton (a process called bone resorption) and new bone tissue is formed (a process called ossification or new bone formation). These processes also control the reshaping or replacement of bone following injuries like fractures but also micro-damage, which occurs during normal activity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Myeloid_tissue">Myeloid tissue</a></td>
      <td>Myeloid tissue, in the bone marrow sense of the word myeloid (myelo- + -oid), is tissue of bone marrow, of bone marrow cell lineage, or resembling bone marrow, and myelogenous tissue (myelo- + -genous) is any tissue of, or arising from, bone marrow; in these senses the terms are usually used synonymously, as for example with chronic myeloid/myelogenous leukemia.\nIn hematopoiesis, myeloid or myelogenous cells are blood cells that arise from a progenitor cell for granulocytes, monocytes, erythrocytes, or platelets (the common myeloid progenitor, that is, CMP or CFU-GEMM), or in a narrower sense also often used, specifically from the lineage of the myeloblast (the myelocytes, monocytes, and their daughter types).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Film_distribution">Film distribution</a></td>
      <td>Film distribution is the process of making a movie available for viewing by an audience. This is normally the task of a professional film distributor, who would determine the marketing strategy for the film, the media by which a film is to be exhibited or made available for viewing, and who may set the release date and other matters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Normal_distribution">Normal distribution</a></td>
      <td>In statistics, a normal distribution (also known as Gaussian, Gauss, or Laplace–Gauss distribution) is a type of continuous probability distribution for a real-valued random variable. The general form of its probability density function is\n\n  \n    \n      \n        f\n        (\n        x\n        )\n        =\n        \n          \n            1\n            \n              σ\n              \n                \n                  2\n                  π\n                \n              \n            \n          \n        \n        \n          e\n          \n            −\n            \n              \n                1\n                2\n              \n            \n            \n              \n                (\n                \n                  \n                    \n                      x\n                      −\n                      μ\n                    \n                    σ\n                  \n                \n                )\n              \n              \n                2\n              \n            \n          \n        \n      \n    \n    {\displaystyle f(x)={\frac {1}{\sigma {\sqrt {2\pi }}}}e^{-{\frac {1}{2}}\left({\frac {x-\mu }{\sigma }}\right)^{2}}}\n  The parameter \n  \n    \n      \n        μ\n      \n    \n    {\displaystyle \mu }\n   is the mean or expectation of the distribution (and also its median and mode), while the parameter \n  \n    \n      \n        σ\n      \n    \n    {\displaystyle \sigma }\n   is its standard deviation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dental_implant">Dental implant</a></td>
      <td>A dental implant (also known as an endosseous implant or fixture) is a prosthesis that interfaces with the bone of the jaw or skull to support a dental prosthesis such as a crown, bridge, denture, or facial prosthesis or to act as an orthodontic anchor. The basis for modern dental implants is a biologic process called osseointegration, in which materials such as titanium or zirconia form an intimate bond to bone.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>OSTEOTECH INC      Item 1A Risk Factors          We are <font color="blue">dependent upon one client</font> who <font color="blue">accounts</font> for <font color="blue">approximately</font> 27prca of     our revenues</td>
    </tr>
    <tr>
      <td>We  are  a  processor  of  <font color="blue">allograft <font color="blue">bone tissue</font></font> for national and     <font color="blue">international</font> not-for-profit <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>During 2005, MTF accounted for     <font color="blue">approximately</font>  27prca  of  our  <font color="blue">consolidated</font>  revenues</td>
    </tr>
    <tr>
      <td>We <font color="blue">entered into</font> a     non-exclusive processing <font color="blue">agreement</font> with MTF in June, 2002, <font color="blue">which expires on</font>     <font color="blue">December </font>31, 2008, and we <font color="blue">entered into</font> a second processing <font color="blue">agreement</font> with     MTF, <font color="blue">which expires on</font> <font color="blue">December </font>31, 2006 unless extended in <font color="blue">accordance with</font>     the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>The loss of MTF as a client or a substantial reduction in the     amount  of <font color="blue">allograft <font color="blue">bone tissue</font></font> which we process for MTF would have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [79]Table of <font color="blue">Contents       </font>     Our  <font color="blue">dependence upon</font> a limited supply of <font color="blue">human donors may curtail</font>     business expansion</td>
    </tr>
    <tr>
      <td>Our <font color="blue">allograft <font color="blue">bone tissue</font></font> processing business <font color="blue">primarily depends upon</font>     the <font color="blue">availability</font> of bone and related <font color="blue">connective tissue from human donors</font>     recovered by our clients, TRO’s and tissue banks that recover donated human     <font color="blue">cadaveric</font> tissue for us or <font color="blue"><font color="blue">international</font>ly</font> from our own efforts</td>
    </tr>
    <tr>
      <td>We rely on     the efforts of not-for-profit donor <font color="blue">procurement</font> agencies, including our     <font color="blue">current clients</font>, to educate the public and foster an <font color="blue">increased willingness</font>     to  donate  <font color="blue">bone tissue</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">organizations</font> may not be able to find a     sufficient number of <font color="blue">persons willing</font> to donate, or may not be willing to     provide, sufficient amounts of tissue to <font color="blue">meet present</font> or <font color="blue">future demand</font> for     either  allograft  bone  tissue  we  distribute  or any <font color="blue">allograft bone</font>     tissue-based osteogenic materials we are developing</td>
    </tr>
    <tr>
      <td>Although we have taken     steps to address this tissue supply problem, we <font color="blue">cannot assure</font> you that these     <font color="blue">efforts will</font> be successful in the future or that we <font color="blue">will otherwise</font> be able     to secure a <font color="blue">sufficient supply</font> of tissue</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">secure enough</font>     <font color="blue">donor tissue</font> to meet our <font color="blue">demands could</font> have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  may need to <font color="blue">secure additional financing</font> to fund our long-term     strategic plan</td>
    </tr>
    <tr>
      <td>We expect to continue to make <font color="blue">investments</font> in our business to support     our <font color="blue"><font color="blue">distribution</font> efforts</font> and <font color="blue">future programs</font> and initiatives, which may     deplete our <font color="blue"><font color="blue">available cash</font> balances</font></td>
    </tr>
    <tr>
      <td>We believe that our <font color="blue">available cash</font>,     cash equivalents, available lines of credit and anticipated <font color="blue">future <font color="blue">cash flow</font></font>     from <font color="blue">operations</font> will be sufficient to meet our <font color="blue">forecasted cash</font> needs in     2006</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">future liquidity</font> and <font color="blue">capital <font color="blue">requirements</font> will depend upon</font>     <font color="blue">numerous factors</font>, including:       •   the progress of our <font color="blue">product <font color="blue">development</font> programs</font> and the need for and     <font color="blue">associated costs</font> relating to <font color="blue"><font color="blue">regulatory</font> approvals</font>, if any, which may be     needed to <font color="blue">commercialize</font> some of our products under <font color="blue">development</font>, or those     <font color="blue">commercialize</font>d products whose <font color="blue">regulatory</font> status may change; and         •   the resources we devote to the <font color="blue">development</font>, <font color="blue">manufacture</font> and marketing     of our services and products</td>
    </tr>
    <tr>
      <td>We may need to <font color="blue">raise additional funds through</font> the issuance of equity     and/or debt financing in <font color="blue">private placements</font> or <font color="blue">public offerings</font> to provide     funds to meet the needs of our long-term strategic plan</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>funds     may not be available, or if available, may not be <font color="blue">available on</font> favorable     terms</td>
    </tr>
    <tr>
      <td>Further <font color="blue">equity <font color="blue">financings</font></font>, if obtained, <font color="blue">may substantially dilute</font> the     interest of our pre-existing shareholders</td>
    </tr>
    <tr>
      <td>Any <font color="blue">additional debt <font color="blue">financings</font></font>     <font color="blue">may contain <font color="blue">restrictive</font> terms</font> that limit our operating <font color="blue">flexibility</font></td>
    </tr>
    <tr>
      <td>As a     result, any future <font color="blue">financings</font> could have a material adverse effect on our     business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our  cash  flows may be <font color="blue">adversely impacted by</font> our <font color="blue">focus on direct</font>     <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td><font color="blue">Commencing </font>in 2001, we began to distribute tissue forms directly to     surgeons  and  hospitals</td>
    </tr>
    <tr>
      <td>We  expect to continue to expand our direct     <font color="blue"><font color="blue">distribution</font> efforts</font> to surgeons and hospitals in future periods, with     ultimately 100prca of our revenues being <font color="blue">derived by</font> these efforts</td>
    </tr>
    <tr>
      <td>This change     in <font color="blue">distribution</font> methodology has impacted and <font color="blue">may <font color="blue">negatively impact</font></font> our     <font color="blue">future <font color="blue">cash flow</font></font></td>
    </tr>
    <tr>
      <td>As a greater percentage of our revenues are generated from     direct  shipments  to  hospitals and other healthcare providers, which     <font color="blue">typically pay invoices</font> more <font color="blue">slowly than</font> our <font color="blue">historical customer base</font>, our     <font color="blue">accounts</font> receivable balances may increase, therefore <font color="blue">negatively impact</font>ing     our                                         21       _________________________________________________________________    [80]Table of <font color="blue">Contents       </font><font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>In addition, as our direct <font color="blue"><font color="blue">distribution</font> efforts</font> increase we may     be  required to expand the size of our tissue inventories, which would     <font color="blue">negatively impact</font> our <font color="blue">cash flow</font></td>
    </tr>
    <tr>
      <td>We face strong <font color="blue">competitive</font> threats from firms with greater financial     resources and <font color="blue">lower costs</font></td>
    </tr>
    <tr>
      <td>The  allograft  <font color="blue">bone tissue</font> we <font color="blue">process competes</font> in the <font color="blue">bone graft</font>     substitute market with autograft <font color="blue">bone tissue</font>, synthetic bone void fillers,     <font color="blue">growth factors</font> and <font color="blue">allograft <font color="blue">bone tissue</font></font> <font color="blue">processed by others</font></td>
    </tr>
    <tr>
      <td><font color="blue">Autograft </font>bone     tissue has <font color="blue">traditionally been</font> the <font color="blue">primary choice</font> for surgeons and we believe     autograft <font color="blue">bone tissue</font> is <font color="blue">still used extensively</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In the     <font color="blue">international</font> marketplace, autograft <font color="blue">bone tissue</font> along with <font color="blue">bone graft</font>     <font color="blue">substitutes</font>, such as bovine <font color="blue">bone tissue</font> and synthetics, currently comprise     most of the <font color="blue">bone graft</font>ing market</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have greater     financial resources than we do</td>
    </tr>
    <tr>
      <td>For <font color="blue">numerous <font color="blue">circumstances</font></font> and procedures     for which autograft <font color="blue">bone tissue</font> <font color="blue">transplantation</font> is either not feasible or     not desirable, there are a number of <font color="blue">competing <font color="blue">alternative</font>s available</font>,     including  allograft  bone  tissue  <font color="blue">processed by others</font> and <font color="blue">bone graft</font>     <font color="blue">substitutes</font></td>
    </tr>
    <tr>
      <td>We believe that a majority of the <font color="blue">cadaveric</font> bone banks operating in the     United  States  are  engaged  in  processing <font color="blue">allograft <font color="blue">bone tissue</font></font> for     <font color="blue">transplantation</font></td>
    </tr>
    <tr>
      <td>Many  of  these <font color="blue">bone tissue</font> banks are not-for-profit     <font color="blue">organizations</font>, and, as such, they may be able to supply processing services     at a lower cost than we can</td>
    </tr>
    <tr>
      <td>Several for-profit companies, certain of which     have <font color="blue">substantially greater resources then</font> we do, are processing, marketing     and <font color="blue">distributing allograft tissue</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with such entities on</font> the     basis of our <font color="blue">advanced processing <font color="blue">technology</font></font> and the quality and quantity of     the <font color="blue">bone tissue</font> our <font color="blue">processing yields</font></td>
    </tr>
    <tr>
      <td>Since we introduced our allograft     <font color="blue">bone tissue</font> processing <font color="blue">technology</font> in 1987, certain competing <font color="blue">processors</font> have     claimed to have developed <font color="blue">technology</font> similar to that which we use</td>
    </tr>
    <tr>
      <td>We may     not be able to <font color="blue">compete <font color="blue">successfully</font></font> in the area of <font color="blue">allograft <font color="blue">bone tissue</font></font>     processing and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, our Grafton® DBM and Graftech® Bio-Implant products     have  faced  increasing  <font color="blue">competitive</font>  <font color="blue">pressures as</font> more companies have     developed,  or  have  announced  they  are  developing,  <font color="blue">products with</font>     <font color="blue">characteristics</font> similar to these products</td>
    </tr>
    <tr>
      <td>Certain of those <font color="blue">competitors</font>     have, in turn, partnered with large orthopaedic and spine companies to     market the competing products they have developed</td>
    </tr>
    <tr>
      <td>We expect that this     <font color="blue"><font color="blue">competition</font> will continue</font> in the future</td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font> have     research  and  <font color="blue">development</font>,  marketing  and  other  resources that are     <font color="blue">significantly</font>  greater than ours</td>
    </tr>
    <tr>
      <td>They also offer a full line of metal     implants and other <font color="blue">products used</font> in <font color="blue">spinal surgeries</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">could give them</font> a     <font color="blue">competitive</font> advantage over us since they can offer surgeons a more complete     line of <font color="blue">products than</font> we can</td>
    </tr>
    <tr>
      <td>The <font color="blue">primary advantage</font> of synthetic bone <font color="blue">substitutes</font> and <font color="blue">growth factors</font>     as compared to <font color="blue">allograft <font color="blue">bone tissue</font></font> is that they do not <font color="blue">depend on</font> the     <font color="blue">availability</font> of <font color="blue">donated human tissue</font></td>
    </tr>
    <tr>
      <td>In addition, members of the medical     <font color="blue">community</font> and the <font color="blue">general public may</font> perceive <font color="blue">synthetic materials</font> and growth     factors as safer than allograft-based <font color="blue">bone tissue</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">allograft <font color="blue">bone tissue</font></font>     we <font color="blue">process may</font> be incapable of <font color="blue">competing <font color="blue">successfully</font> with synthetic bone</font>     <font color="blue">substitutes</font> and <font color="blue">growth factors</font> which are developed and <font color="blue">commercialize</font>d by     others,  which  could  have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>are also developing     artificial disks, which would be used to replace a patient’s own injured,     <font color="blue">degenerated</font>  or <font color="blue">diseased spinal disks</font></td>
    </tr>
    <tr>
      <td>If these disks are <font color="blue">successfully</font>     developed and <font color="blue">commercialize</font>d, they                                         22       _________________________________________________________________    [81]Table of <font color="blue">Contents       </font>could have a <font color="blue">negative impact on</font> our bio-implant business and, therefore,     have a material adverse effect on our <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We rely on our <font color="blue"><font color="blue">independent</font> sales agents</font> and <font color="blue">sales <font color="blue">representatives</font></font> to     <font color="blue"><font color="blue">educate surgeons</font> <font color="blue">concerning</font></font> our products and to market our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends largely upon arrangements</font> we have <font color="blue">with <font color="blue">independent</font></font>     sales  agents  and <font color="blue">sales <font color="blue">representatives</font></font> whereby they <font color="blue">educate surgeons</font>     <font color="blue">concerning</font>  our  products</td>
    </tr>
    <tr>
      <td>These  <font color="blue">independent</font>  sales agents and sales     <font color="blue">representatives</font>  may  terminate  their <font color="blue">relationship with us</font>, or devote     insufficient  sales  efforts  to  our  products</td>
    </tr>
    <tr>
      <td>We do not control our     <font color="blue"><font color="blue">independent</font> sales agents</font> and they may not be successful in <font color="blue">implementing</font> our     marketing plans</td>
    </tr>
    <tr>
      <td>Our failure to attract and retain skilled <font color="blue">independent</font> sales     agents  and  sale  <font color="blue">representatives</font> could have an adverse effect on our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">revenues will depend upon <font color="blue">reimbursement</font> from public</font> and private     insurers and <font color="blue">national health systems</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">continued ability</font> of our clients to pay our processing charges for     the processing of <font color="blue">allograft <font color="blue">bone tissue</font></font> depends upon our or our clients’     ability to distribute processed <font color="blue">allograft <font color="blue">bone tissue</font></font> and <font color="blue">collect fees from</font>     end-users, which are <font color="blue">typically hospitals</font></td>
    </tr>
    <tr>
      <td>The ability of hospitals to pay     fees  for <font color="blue">allograft <font color="blue">bone tissue</font></font> depends in part on the extent to which     <font color="blue">reimbursement</font> for the costs of <font color="blue">such materials</font> and related <font color="blue"><font color="blue">treatments</font> will</font>     continue to be available from <font color="blue">government</font> health administration authorities,     private  <font color="blue">health coverage insurers</font> and other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>We may have     <font color="blue"><font color="blue">difficult</font>y</font>  <font color="blue">gaining market acceptance</font> for our products and services if     <font color="blue">government</font> and third-party payors do not <font color="blue">provide adequate coverage</font> and     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>The medical <font color="blue">community</font> could choose not to use our <font color="blue">allograft <font color="blue">bone tissue</font></font>     products</td>
    </tr>
    <tr>
      <td>We believe the market for <font color="blue">allograft <font color="blue">bone tissue</font></font> will continue to be     <font color="blue">based primarily upon</font> the use of <font color="blue">such products by physicians specializing</font> in     the orthopaedic, spine, neurological and oral/maxillofacial surgical areas</td>
    </tr>
    <tr>
      <td>Our  future  <font color="blue">growth depends</font> in part upon such physicians’ wider use of     <font color="blue">allograft <font color="blue">bone tissue</font></font> as an <font color="blue">alternative</font> to autograft <font color="blue">bone tissue</font> and other     <font color="blue">available materials</font> and <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>We have tried to <font color="blue">educate physicians</font>     through our <font color="blue">marketing activities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future efforts</font> in this regard may fail     to <font color="blue">generate additional demand</font> for our <font color="blue">allograft tissue forms</font></td>
    </tr>
    <tr>
      <td><font color="blue">Governmental </font><font color="blue">regulation could restrict</font> the use of our products or our     <font color="blue">procurement</font> of tissue</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, the <font color="blue">procurement</font> and <font color="blue">transplantation</font> of allograft     <font color="blue">bone tissue</font> is subject to federal law pursuant to NOTA, a criminal statute     which  prohibits  the  purchase and sale of human organs used in human     <font color="blue">transplantation</font>,  including  bone  and  related  tissue, for “valuable     <font color="blue">consideration</font></td>
    </tr>
    <tr>
      <td>”  NOTA  <font color="blue">permits reasonable payments associated with</font> the     removal,  <font color="blue">transportation</font>,  processing,  preservation, quality control,     <font color="blue">implantation</font> and storage of human <font color="blue">bone tissue</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">provide services</font> in all of     these areas, with the exception of removal and <font color="blue">implantation</font>, and receive     payments for all <font color="blue">such services</font></td>
    </tr>
    <tr>
      <td>If NOTA is interpreted or enforced in a manner     which prevents us from receiving payment for services we render or which     <font color="blue">prevents us from paying</font> TRO’s or certain of our clients for the services     they render for us, our business could be materially, adversely affected</td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________    [82]Table of <font color="blue">Contents       </font>     We are engaged through our <font color="blue">direct sales</font> and <font color="blue">marketing employees</font> and our     <font color="blue">independent</font> <font color="blue">sales <font color="blue">representatives</font></font> in <font color="blue">ongoing efforts designed</font> to educate the     medical <font color="blue">community</font> as to the benefits of processed <font color="blue">allograft <font color="blue">bone tissue</font></font> and     in particular our <font color="blue">allograft <font color="blue">bone tissue</font></font> forms, and we intend to continue our     <font color="blue">educational activities</font></td>
    </tr>
    <tr>
      <td>Although we believe that NOTA <font color="blue">permits payments</font> in     <font color="blue"><font color="blue">connection</font> with</font> these <font color="blue">educational efforts as reasonable payments associated</font>     with the processing, <font color="blue">transportation</font> and <font color="blue">implantation</font> of our <font color="blue">allograft bone</font>     tissue forms, payments in <font color="blue"><font color="blue">connection</font> with</font> such <font color="blue">education efforts</font> are not     <font color="blue">exempt from</font> NOTA’s <font color="blue">restrictions</font> and our <font color="blue">inability</font> to make <font color="blue">such payments</font> in     <font color="blue"><font color="blue">connection</font> with</font> our <font color="blue">education efforts</font> may prevent us from paying our sales     <font color="blue">representatives</font> for their <font color="blue">education efforts</font> and <font color="blue">could adversely affect</font> our     business and prospects</td>
    </tr>
    <tr>
      <td>No <font color="blue">federal agency</font> or court has determined whether     NOTA  is,  or will be, applicable to every <font color="blue">allograft <font color="blue">bone tissue</font></font>-based     material, which our <font color="blue">processing technologies may generate</font></td>
    </tr>
    <tr>
      <td>Assuming that NOTA     applies to our processing of <font color="blue">allograft <font color="blue">bone tissue</font></font>, we believe that we     comply  with NOTA, but there can be no assurance that more <font color="blue">restrictive</font>     <font color="blue">interpretations</font> of, or <font color="blue">amendments</font> to, NOTA will not be adopted in the future     which  would  call  <font color="blue">into question one</font> or more aspects of our method of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The US <font color="blue">federal health care laws apply</font> to <font color="blue">certain aspects</font> of our     business  if a <font color="blue">customer submits</font> a claim for an item or service that is     <font color="blue">reimbursed under</font> Medicare, Medicaid or most other federally-funded health     care programs</td>
    </tr>
    <tr>
      <td>Of <font color="blue">principal importance</font> to us, federal law prohibits unlawful     <font color="blue">inducements</font> for the referral of business reimbursable under federally-funded     health  care  programs (the “Anti-Kickback Law”), <font color="blue">such as remuneration</font>     provided to physicians to <font color="blue">induce them</font> to <font color="blue">use certain tissue products</font> or     <font color="blue">medical devices reimbursable by</font> <font color="blue">Medicare or Medicaid</font></td>
    </tr>
    <tr>
      <td>The Anti-Kickback Law     is subject to evolving <font color="blue">interpretations</font></td>
    </tr>
    <tr>
      <td>If a <font color="blue">government</font>al authority were to     conclude that we are not in <font color="blue">compliance with</font> applicable laws and <font color="blue">regulations</font>,     Osteotech, its officers and employee, could be subject to <font color="blue">severe criminal</font>     and <font color="blue">civil penalties</font> including, for example, exclusion from participation as     a supplier of product to <font color="blue">beneficiaries covered by</font> <font color="blue">Medicare or Medicaid</font></td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">extensively regulated by federal</font> and certain state     agencies in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> these <font color="blue">requirements</font> may     subject  us to <font color="blue">administrative</font> or judicial sanctions, such as the FDA’s     refusal to clear pending applications, warning letters, product recalls,     product seizures, total or <font color="blue">partial suspension</font> of production or <font color="blue">distribution</font>,     <font color="blue">civil penalties</font>, injunctions and/or criminal prosecution</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, the <font color="blue">allograft <font color="blue">bone tissue</font></font>s that we process are     regulated by the FDA as human tissue-based products under section 361 of the     Public Health Service Act, and under certain <font color="blue">circumstances</font>, may be regulated     as a medical device under the Food, Drug, and Cosmetic Act</td>
    </tr>
    <tr>
      <td>FDA  <font color="blue">regulations</font> generally do not require that human tissue-based     products be cleared or approved before they are marketed</td>
    </tr>
    <tr>
      <td>We are, however,     required to register and list these <font color="blue">products with</font> the FDA and to <font color="blue">comply with</font>     <font color="blue">regulations</font> <font color="blue">concerning</font> tissue donor screening and testing, and related     procedures  and  record  keeping</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">periodically</font> inspects tissue     <font color="blue">processors</font> to determine <font color="blue">compliance with</font> these <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Effective </font>in     May 2005, the FDA’s “Current Good Tissue Practice” <font color="blue">regulations</font> went into     effect, which impose <font color="blue">requirements</font> on the <font color="blue">manufacture</font> of human tissue-based     products,  including tissue recovery, donor screening, donors testing,     processing, storage, labeling, packaging and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>We believe we     <font color="blue">comply with</font> all aspects of the <font color="blue">Current Good Tissue Practice </font><font color="blue">regulations</font>,     <font color="blue">although there</font> can be no assurance that we <font color="blue">will comply</font> or <font color="blue">will comply</font> in the     future</td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________    [83]Table of <font color="blue">Contents       </font>     Allograft <font color="blue">bone tissue</font> and tissue banking activities, such as tissue     donation and recovery and <font color="blue">tissue processing</font>, are regulated in virtually all     countries in which we operate outside the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font>     schemes and specific <font color="blue">requirements</font> for these products and <font color="blue">activities vary</font>     from  country-to-country</td>
    </tr>
    <tr>
      <td>There are no common or harmonized <font color="blue">regulatory</font>     approvals or programs for these products and activities, such as there are     for <font color="blue">medical devices marketed</font> in the <font color="blue">European Union</font></td>
    </tr>
    <tr>
      <td>We believe that we     <font color="blue">comply with</font> the national <font color="blue">regulations</font> in the countries in which we currently     operate or in the countries we plan to operate in the future, <font color="blue">although there</font>     can be <font color="blue">no assurances</font> that we will be able to do so in the future</td>
    </tr>
    <tr>
      <td>We <font color="blue">may face lawsuits</font> or <font color="blue">government</font>al enforcement activities based on     <font color="blue">hazardous waste</font> we generate in our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">allograft <font color="blue">bone tissue</font></font> processing in both the <font color="blue">United States</font> and     Europe  generates  waste  materials,  which, in the <font color="blue">United States</font>, are     classified  as  medical waste and/or <font color="blue">hazardous waste</font> under <font color="blue">regulations</font>     <font color="blue">promulgated by</font> the <font color="blue">United States</font> Environmental Protection Agency and the New     Jersey  Department of Environmental Protection</td>
    </tr>
    <tr>
      <td>We segregate our waste     materials and dispose of them through a licensed <font color="blue">hazardous waste</font> transporter     in <font color="blue">compliance with</font> applicable <font color="blue">regulations</font> in both the <font color="blue">United States</font> and     Europe</td>
    </tr>
    <tr>
      <td>Our failure to fully <font color="blue">comply with</font> any environmental <font color="blue">regulations</font> could     result in the imposition of penalties, sanctions or, in some cases, private     lawsuits,  <font color="blue">which could</font> have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may incur losses from <font color="blue">product liability</font> lawsuits</font></td>
    </tr>
    <tr>
      <td>The testing and use of human <font color="blue">allograft <font color="blue">bone tissue</font></font>, bovine tissue     products and medical devices <font color="blue">manufacture</font>d by others and which we distribute,     <font color="blue">entail inherent risks</font> of <font color="blue">medical complications</font> for patients and therefore     may result in <font color="blue">product liability</font> claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Further, our <font color="blue">agreement</font>s     with   our  allograft  bone  tissue  processing  clients  provide  for     <font color="blue">indemnification by us</font> for <font color="blue">liabilities</font> arising out of defects in allograft     <font color="blue">bone tissue</font> they distribute, which is caused by our processing</td>
    </tr>
    <tr>
      <td>We presently maintain <font color="blue">product liability</font> insurance in the amount of     dlra30 million per occurrence and per year in the aggregate</td>
    </tr>
    <tr>
      <td>We may be unable     to maintain <font color="blue">such insurance</font> in the future and <font color="blue">such insurance</font> may not be     sufficient to cover all claims made <font color="blue">against us</font> or all types of <font color="blue">liabilities</font>,     which may be asserted <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends upon</font> the <font color="blue">continued contributions</font> of our executive     officers  and  scientific and <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">competition</font> for     qualified  personnel  is  intense, and the loss of services of our key     personnel, particularly members of senior management, <font color="blue">could adversely affect</font>     our business</td>
    </tr>
    <tr>
      <td>If we are unable to enforce our patents or if it is determined that we     <font color="blue">infringe patents</font> held by others it could damage our business</td>
    </tr>
    <tr>
      <td>We  consider  our <font color="blue">allograft <font color="blue">bone tissue</font></font> processing <font color="blue">technology</font> and     procedures  <font color="blue">proprietary</font>  and  <font color="blue">rely primarily on patents</font> to protect our     <font color="blue">technology</font>  and <font color="blue">innovations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Consultants </font><font color="blue">employed by third parties</font> and     persons working in conjunction with <font color="blue">medical institutions</font> unaffiliated with     us have <font color="blue">conducted significant research</font> and <font color="blue">development</font> for our products</td>
    </tr>
    <tr>
      <td>Accordingly, disputes                                         25       _________________________________________________________________    [84]Table of <font color="blue">Contents       </font>may arise <font color="blue">concerning</font> the <font color="blue">proprietary</font> rights to information applied to our     projects, which have been <font color="blue">independent</font>ly developed, <font color="blue">by such consultants</font> or     <font color="blue">medical institutions</font></td>
    </tr>
    <tr>
      <td>In addition, although we have attempted to protect our     <font color="blue">technology</font>  with  patents,  our  <font color="blue">existing patents may prove invalid</font> or     <font color="blue">unenforceable as</font> to products or <font color="blue">services marketed by</font> our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">pending patent applications may</font> not result in <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>Moreover, our     existing or <font color="blue">future products</font> and <font color="blue">technologies could</font> be found to infringe the     patents of others</td>
    </tr>
    <tr>
      <td><font color="blue">Prosecuting </font>and defending <font color="blue">patent lawsuit</font>s is very expensive</td>
    </tr>
    <tr>
      <td>We are     committed to <font color="blue">aggressively</font> asserting and defending our <font color="blue">technology</font> and related     intellectual property, which we have spent a <font color="blue">significant amount</font> of money to     develop</td>
    </tr>
    <tr>
      <td>In addition, the industry in which we compete is known for having a     great deal of <font color="blue">litigation involving patents</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could</font> cause us to     <font color="blue">become involved</font> in <font color="blue">new patent litigation</font> in the future</td>
    </tr>
    <tr>
      <td>The expense of     prosecuting or defending these <font color="blue">future lawsuits <font color="blue">could also</font></font> have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we were to lose a <font color="blue">patent lawsuit</font> in which another party is asserting     that our products infringe its patents, we <font color="blue">would likely</font> be <font color="blue">prohibited from</font>     marketing those products and <font color="blue">could also</font> be liable for <font color="blue">significant damages</font></td>
    </tr>
    <tr>
      <td>Either or both of these results may have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we lose a patent     lawsuit  in  which  we  are claiming that another party’s products are     infringing our patents and thus, are unable to enforce our patents, it may     have a material adverse effect on our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue"><font color="blue">preferred stock may</font> adversely affect rights</font> of common     <font color="blue">stockholders</font> or discourage a takeover</td>
    </tr>
    <tr>
      <td>Under our amended and <font color="blue">restated certificate</font> of <font color="blue">incorporation</font>, our Board     of Directors has the authority to issue up to 5cmam000cmam000 shares of preferred     stock and to determine the price, rights, preferences and privileges of     those <font color="blue">shares without</font> any <font color="blue">further vote</font> or <font color="blue">action by</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The     rights  of  the holders of <font color="blue"><font color="blue">common stock</font> will</font> be subject to, and may be     <font color="blue">adversely affected by</font>, the rights of the holders of any shares of preferred     stock that may be issued in the future</td>
    </tr>
    <tr>
      <td>In January, 1996, our board of <font color="blue"><font color="blue">directors</font> authorized shares</font> of Series E     Preferred Stock in <font color="blue"><font color="blue">connection</font> with</font> its adoption of a <font color="blue">stockholder rights</font>     plan, under which we <font color="blue">issued rights</font> to purchase <font color="blue">Series E Preferred Stock </font>to     holders of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Upon certain triggering events, such rights     <font color="blue">become exercisable</font> to <font color="blue">purchase <font color="blue">common stock</font></font> (or, in the <font color="blue">discretion</font> of our     board of <font color="blue">directors</font>, Series E Preferred Stock) at a <font color="blue">price substantially</font>     <font color="blue">discounted from</font> the <font color="blue">then current market price</font> of the <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">stockholder rights</font> plan could generally discourage a merger or <font color="blue">tender offer</font>     involving our securities that is not <font color="blue">approved by</font> our <font color="blue">Board of Directors </font>by     increasing the cost of <font color="blue">effecting</font> any <font color="blue">such transaction</font> and, <font color="blue">accordingly</font>,     could have an adverse impact on <font color="blue">stockholders</font> who might want to vote in favor     of such merger or <font color="blue">participate</font> in such <font color="blue">tender offer</font></td>
    </tr>
    <tr>
      <td>While we have <font color="blue">no present intention</font> to authorize any <font color="blue">additional series</font>     of preferred stock, such issuance, while providing desirable <font color="blue">flexibility</font> in     <font color="blue"><font color="blue">connection</font> with</font> possible acquisitions and other corporate purposes, could     also  have the effect of making it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to     acquire a majority of our <font color="blue">outstanding voting stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">preferred stock may</font>     have other rights, including <font color="blue">economic rights senior</font> to the <font color="blue">Common Stock</font>,     and, as a result, the issuance thereof could have a material adverse effect     on the market value of the <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>